Product
VRx-3996
Aliases
Nanatinostat
1 clinical trial
2 indications
Indication
Epstein-Barr Virus Associated LymphomaIndication
Lymphoproliferative DisordersClinical trial
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid MalignanciesStatus: Completed, Estimated PCD: 2023-04-01